These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22811222)

  • 41. Zoledronic acid in lung cancer with bone metastases: a review.
    Isla D; Afonso R; Bosch-Barrera J; Martínez N
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):421-6. PubMed ID: 23560837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?
    Waldert M; Klatte T; Remzi M; Sinzinger H; Kratzik C
    World J Urol; 2012 Apr; 30(2):233-7. PubMed ID: 21559805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 44. [Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer].
    Kamoto T
    Clin Calcium; 2011 Mar; 21(3):465-71. PubMed ID: 21358069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
    Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
    Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Skeletal-related events in prostate cancer.
    Smith MR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
    [No Abstract]   [Full Text] [Related]  

  • 47. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
    Saad F; Segal S; Eastham J
    Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.
    Lam MG; de Klerk JM; Zonnenberg BA
    J Palliat Med; 2009 Jul; 12(7):649-51. PubMed ID: 19594354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.
    Okegawa T; Higaki M; Matsumoto T; Kase H; Murata A; Noda K; Noda H; Asaoka H; Oshi M; Tomoishi J; Uchida H; Higashihara E; Nutahara K;
    Anticancer Res; 2014 Aug; 34(8):4415-20. PubMed ID: 25075079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of zoledronic acid in pediatric cancer patients.
    August KJ; Dalton A; Katzenstein HM; George B; Olson TA; Wasilewski-Masker K; Rapkin LB
    Pediatr Blood Cancer; 2011 Apr; 56(4):610-4. PubMed ID: 21298747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Progress in treatment of metastatic tumors in the bone by bisphosphonate].
    Dong M; Chen XP; Feng FY
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):801-3. PubMed ID: 18396633
    [No Abstract]   [Full Text] [Related]  

  • 52. Moving into the future: treatment of bone metastases and beyond.
    Hortobagyi GN
    Cancer Treat Rev; 2005; 31 Suppl 3():9-18. PubMed ID: 16249057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bisphosphonates: prevention of bone metastases in prostate cancer.
    Saad F; Lattouf JB
    Recent Results Cancer Res; 2012; 192():109-26. PubMed ID: 22307372
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone markers for monitoring efficacy in patients 
with bone metastases receiving zoledronic acid: 
a review of published data.
    Huang Q; Ouyang X
    Int J Biol Markers; 2013 Sep; 28(3):242-8. PubMed ID: 23661577
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.
    Fulfaro F; Leto G; Badalamenti G; Arcara C; Cicero G; Valerio MR; Di Fede G; Russo A; Vitale A; Rini GB; Casuccio A; Intrivici C; Gebbia N
    J Chemother; 2005 Oct; 17(5):555-9. PubMed ID: 16323446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan.
    Chiang PH; Wang HC; Lai YL; Chen SC; Yen-Hwa W; Kok CK; Ou YC; Huang JS; Huang TC; Chao TY
    J Cancer Res Ther; 2013; 9(4):653-9. PubMed ID: 24518712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.